Stock

Target doubles bonuses for salaried employees as profits surge

Target is ratcheting up bonuses for salaried employees, including leaders in stores and across supply chains, thanks to a surge in profits.

The move comes thanks to $2 billion in additional profit growth for 2023, a company spokesperson said in a statement Thursday.

Target’s stock surged in November after having fallen for much of 2023 as the company reported it had lowered costs to offset a slowdown in consumer discretionary spending. Since mid-November, Target’s shares have climbed 54%.

The company spokesperson confirmed that eligible Target employees received 100% of their 2023 bonuses, up from 50% the previous year.

“We’re rewarding our team accordingly,” the spokesperson said.

In-store managers and supply-chain operation leaders are among those who will get the increased bonuses, the statement said.

Bloomberg first reported the news.

The profits bump is part of a trend of stronger earnings growth for companies across the board as inflation cools and labor productivity surges to all-time highs.

On Thursday, stock indexes closed at all-time highs.

The bonuses don’t apply to Target’s hourly employees, whose pay starts at $15 an hour except in markets like California, where it rises to $19.75. That compares with a starting hourly wage of $14 for Walmart workers.

This post appeared first on NBC NEWS

You May Also Like

Investing

2023 was a relatively lackluster year, silver largely traded on volatility between US$22 and US$25 per ounce. The white metal started 2024 with less...

Latest News

Dong’s experience, both as head of the People’s Liberation Army Navy (PLAN) as well as operational assignments in the Chinese military’s Eastern and Southern...

Investing

The US was one of the world’s top silver producers in 2023, recording output of 1,000 metric tons (MT). While that’s far below first-place...

Investing

The Canadian pharmaceutical market is the eighth largest in the world and accounts for 2.2 percent of the global prescription drug market. But what...

Disclaimer: GreatWallStreetPublisher.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 GreatWallStreetPublisher.com

Exit mobile version